Imatinib Grindeks

Imatinib, the active ingredient in Imatinib Grindeks, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib targets specific tyrosine‑kinase driven cancers and is used in the following indications: - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by targeting BCR‑ABL positive blasts. - Gastrointestinal stromal tumor (GIST): inhibits KIT‑driven tumor growth, leading to disease control.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Muscle cramps: intermittent painful tightening of muscles. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - Neutropenia: significant drop in white blood cells increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: reduced cardiac function, especially in patients with pre‑existing heart disease.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular complete blood count assessments. - Assess liver function: check hepatic enzymes periodically. - Evaluate cardiac status: baseline and periodic ECGs for patients with cardiac history. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Use caution in pregnancy: risk‑benefit assessment required. - Store at room temperature: keep in the original pack, protect from moisture.

Imatinib can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce therapeutic exposure. - Antacids containing aluminum or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Diuretics (e.g., furosemide): increased risk of fluid retention and electrolyte imbalance.